China wants more imported drugs; takes action for faster approval

20 March 2017
china-large

Multinational pharma companies have long been complaining that it takes too long to get their drugs into the Chinese market, reports The Pharma Letter’s local correspondent Wang Fangqing.

The complaints were heard. On March 17, China’s Food and Drug Administration issued a draft titled ‘amended management for imported drugs registration,’ which is for public opinion until April 20.

According to the draft, China no longer requires imported drugs to get the New Drug Application approval in their home countries before applying for the registration in China.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical